Clinical Trial News and Research

RSS

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.

20 Nov 2014

Scientists discover second wave of heart muscle inflammation within a week after heart attack

Results of a new study challenge the current consensus in cardiology that peak myocardial edema, or heart muscle swelling, only occurs just after a myocardial infarction, or heart attack. In the study, presented as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions 2014 and published simultaneously in the Journal of the American College of Cardiology, scientists discovered a second wave of swelling and inflammation occurs within a week of a heart attack.

19 Nov 2014

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.

19 Nov 2014

Biomarker-directed chemotherapy detrimental in NSCLC

Treating non-small-cell lung cancer patients with chemotherapy customised according to expression of BRCA1 and receptor-associated protein 80 does not improve progression-free survival compared with nonselected, cisplatin-based chemotherapy, show study findings.

19 Nov 2014

Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific, Inc., a molecular diagnostics company, today announced it has submitted its Group B Strep assay to the U.S. Food and Drug Administration for 510(k) clearance.

19 Nov 2014

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease.

18 Nov 2014

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.

18 Nov 2014

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).

18 Nov 2014

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

18 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US.

14 Nov 2014

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).

14 Nov 2014

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

Clinical Trial News and Research

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Scientists discover second wave of heart muscle inflammation within a week after heart attack

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Biomarker-directed chemotherapy detrimental in NSCLC

Great Basin Scientific seeks FDA approval for Group B Strep assay

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Investigational treatment shows promise against Marfan syndrome

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

TapImmune signs new collaborative research agreement with VGTI Florida

New oral medication shows promise in treating fibromyalgia

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

Adding ezetimibe to statin therapy reduces cardiovascular events

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

Study gives a roadmap for future brain cancer vaccines

Genticel completes patient enrollment for ProCervix phase II study

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer